Statement: There were several patients who contracted Pneumonia in the primary trial.
Primary_evidence: Adverse Events 1:   Total: 20/52 (38.46%)   Febrile bone marrow aplasia * 5/52 (9.62%)   Febrile neutropenia * 6/52 (11.54%)   Leukopenia * 6/52 (11.54%)   Atrial tachycardia * 1/52 (1.92%)   Vomiting * 1/52 (1.92%)   Tooth loss * 1/52 (1.92%)   Hyperthermia * 1/52 (1.92%)   Malaise * 1/52 (1.92%)   Pyrexia * 1/52 (1.92%)   Impaired healing * 3/52 (5.77%)   Inflammation * 1/52 (1.92%)